Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Ziekenhuis van diagnose beïnvloedt overleving bij peritoneale metastasen
apr 2017 | Maag-darm-leveroncologie